Anaemia of chronic kidney disease
Anaemia is a part of chronic kidney disease (CKD), it follows the loss of functional kidney tissue and inability to produce adequate amount of erythropoietin. Anaemia starts when half of glomerular filtration is lost. In patients with diabetes, congestive heart failure and inflammatory diseases, anaemia is disproportion ally more advanced than renal failure. Anaemia of CKD is successfully treated by erythropoietin analogs. With correction of haemoglobin symptoms of anaemia disappear, blood transfusions are avoided, physical performance increases, intellectual and sexual function is improved. Correction of haemoglobin to 100 g/L brings striking improvement in quality of life, but with further increase in haemoglobin improvement is less noticeable. Improvement in renal function with correction of anaemia by erythropoietin was not proven. Studies of the effect of anaemia correction by erythropoietin on mortality uniformly documented increased mortality with rise in haemoglobin, that prompted American and European medical agencies to recommend lower target haemoglobin levels (110 to 120 g/L) for predialysis, dialysis and transplanted patients treated by erythropoietin.
Key words:
Anaemia of chronic kidney disease, chronic kidney disease, terminal renal failure, erythropoietin, mortality, quality of life
OGLASI
